BridgeBio Pharma, Inc. BBIO

BBIO Company Overview

BridgeBio Pharma, Inc. is a U.S.-based biotechnology company focused on developing therapies for genetic diseases and cancers with well-characterized molecular drivers. The company operates primarily in the biopharmaceutical industry, with an emphasis on rare diseases, inherited conditions, and precision oncology. BridgeBio’s business model combines centralized drug development and capital allocation with a network of subsidiary companies dedicated to specific therapeutic programs. Its primary revenue drivers historically have included licensing agreements, collaboration revenue, and, increasingly, commercial product sales tied to approved therapies.

The company was founded in 2015 by Neil Kumar and other biotechnology investors and scientists with the goal of accelerating the development of genetically targeted medicines through a decentralized structure. BridgeBio expanded through internal research programs, acquisitions, and strategic partnerships, building a portfolio spanning cardiovascular disease, dermatology, neurology, endocrinology, and oncology. The company has differentiated itself through its “hub-and-spoke” operating model, which allows individual programs to operate with scientific focus while leveraging centralized infrastructure, regulatory expertise, and financing capabilities.